Company Profiles

driven by the PitchBook Platform

Artios Pharma

Description

Developer of deoxyribonucleic acid (DNA) Damage Response (DDR) cancer therapies. The company provides cancer treatment therapies through deoxyribonucleic acid damage response (DDR) pathways to allow mutations to their deoxyribonucleic acid (DNA) so that they can evolve.

2015

Founded

PRIVATE

Status

1-10

Employees

Series A

Latest Deal Type

$32.9M

Latest Deal Amount

$32.9M

Total Amount Raised

Description

Developer of deoxyribonucleic acid (DNA) Damage Response (DDR) cancer therapies. The company provides cancer treatment therapies through deoxyribonucleic acid damage response (DDR) pathways to allow mutations to their deoxyribonucleic acid (DNA) so that they can evolve.

Website:

www.artiospharma.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

Maia, Building 270 Babraham Research Campus Cambridge CB22 3ATEngland +44 (0)12 2380 4180
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Artios Pharma's full profile, request a free trial.

    Artios Pharma Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Artios Pharma Investors (7)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    AbbVie VenturesCorporate Venture CapitalMinority000 0000000 0000
    Arix BioscienceVenture CapitalMinority000 0000000 0000
    Babraham Bioscience TechnologiesAccelerator/IncubatorMinority000 0000000 0000
    Merck VenturesCorporate Venture CapitalMinority000 0000000 0000
    Sixth Element CapitalVenture CapitalMinority000 0000000 0000
    AbbVie Ventures Corporate Venture Capital
    Arix Bioscience Venture Capital
    Babraham Bioscience Technologies Accelerator/Incubator
    Merck Ventures Corporate Venture Capital
    Sixth Element Capital Venture Capital

    Artios Pharma Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Niall Martin Ph.DChief Executive Officer & Board Member
    Andrew MunceyChief Financial Officer & Company Secretary
    Nick Staples Ph.DChief Business Officer
    Simon Boulton Ph.DVice President, Scientific Strategy
    Peter Harris MDChief Medical Officer
    Niall Martin Ph.D Chief Executive Officer & Board Member
    Andrew Muncey Chief Financial Officer & Company Secretary
    Nick Staples Ph.D Chief Business Officer
    Simon Boulton Ph.D Vice President, Scientific Strategy
    Peter Harris MD Chief Medical Officer

    Artios Pharma Board Members (10)

    NameRepresentingRoleSinceContact
    Info
    Alicia Irurzun-LafitteSelfBoard Observer000 0000
    Alicia Irurzun-LafitteMerck VenturesPrincipal000 0000
    Bobby Soni Ph.DTouchstone InnovationsDirector of Healthcare Investments000 0000
    Hakan Goker Ph.DMerck VenturesSenior Investment Director000 0000
    Hamish Cameron MDSV Health InvestorsOperating Partner000 0000
    Alicia Irurzun-Lafitte Board Observer Self
    Alicia Irurzun-Lafitte Principal Merck Ventures
    Bobby Soni Ph.D Director of Healthcare Investments Touchstone Innovations
    Hakan Goker Ph.D Senior Investment Director Merck Ventures
    Hamish Cameron MD Operating Partner SV Health Investors
    Request full access to PitchBook